State of New Jersey Common Pension Fund D Purchases 249 Shares of Lantheus Holdings, Inc. $LNTH

State of New Jersey Common Pension Fund D raised its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 25,197 shares of the medical equipment provider’s stock after purchasing an additional 249 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Lantheus were worth $2,063,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Signaturefd LLC increased its stake in Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 116 shares in the last quarter. Quarry LP increased its stake in Lantheus by 2,350.0% in the first quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock valued at $48,000 after purchasing an additional 470 shares in the last quarter. Hughes Financial Services LLC bought a new stake in Lantheus during the 1st quarter worth approximately $81,000. GAMMA Investing LLC increased its stake in Lantheus by 29.3% during the 1st quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider’s stock worth $128,000 after purchasing an additional 298 shares in the last quarter. Finally, AlphaQuest LLC increased its stake in Lantheus by 252.5% during the 1st quarter. AlphaQuest LLC now owns 1,653 shares of the medical equipment provider’s stock worth $161,000 after purchasing an additional 1,184 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Truist Financial set a $63.00 target price on Lantheus and gave the stock a “hold” rating in a research note on Monday, August 11th. William Blair reissued a “market perform” rating on shares of Lantheus in a research note on Wednesday, July 16th. JMP Securities lowered their target price on Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a research note on Thursday, August 7th. Mizuho lowered their target price on Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, August 7th. Finally, TD Cowen lowered their target price on Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, September 15th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $74.50.

Lantheus Trading Down 2.5%

NASDAQ:LNTH opened at $55.88 on Thursday. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $118.21. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. The business has a 50 day moving average price of $54.22 and a two-hundred day moving average price of $70.73. The company has a market cap of $3.80 billion, a P/E ratio of 14.86 and a beta of 0.09.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The firm had revenue of $92.51 million during the quarter. As a group, analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 6,812,000 shares of company stock valued at $382,427,380. Insiders own 1.50% of the company’s stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.